Arkema (V1S)

The Strategic Verdict

This Forbes article is a massive structural validation for long-term Lightwave shareholders. For years, the bears argued that Lightwave was a standalone science project trying to force its way into the market.

Now, the U.S. government and GlobalFou

11/06 , maybe you're right!

Here are a few of those drugs:
Ebglyss (IL-13)Adbry (IL-13)Nemluvio (IL-31 receptor)Late-stage agents such as zumilokibart. 

When was it publiced? Maybe this why on 12june there was a huge spike on Jan 2027 15 options??

You ate wrong again! Not all Halozyme targets are public info for obvious competitive reasons.
There are number of other drugs in the class of Dupixent that halozyme might have an exclusive non-disclosed contract for. Here are a few of those drugs:

Of course they did not buy because they knew the regulation. Their families did buy instead.

Uxin Reports Unaudited Financial Results for the Quarter Ended March 31, 2026June 16, 2026 3:00 AM
PR Newswire (US) class="legendSpanClass"BEIJING, class="legendSpanClass"June 16, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company

DXC Expands Relationship with Norske Skog to Modernize Network and Technology OperationsJune 16, 2026 3:00 AM
PR Newswire (US) Multi-year partnership delivers a modern, secure network solution while broadening DXC's role across Norske Sko

Solidion Technology Announced AI-Assisted Design and Manufacturing Technology of Bipolar Solid-State Batteries for Space Vehicles, Ground, Sea, Air and InfrastructureJune 16, 2026 3:00 AM
PR Newswire (US) The company's revolutionary, pate

Elite Tech, Accessible Price - Introducing the Logitech G3 Series Mouse and Keyboard for PC GamingJune 16, 2026 3:05 AM
Business Wire Elite Precision - Unleash pro-grade speed with the G305 X SUPERLIGHT gaming mouse and G316 X 98 gaming keyboard. Featur

You ate wrong again! Not all Halozyme targets are public info for obvious competitive reasons.
There are number of other drugs in the class of Dupixent that halozyme might have an exclusive non-disclosed contract for. Here are a few of those drugs:
Late-stage agents such as zumilokibar

Unilever Scales Digital Twins Across Global Manufacturing Network with AccentureJune 16, 2026 2:59 AM
Business WireUnilever (LON: ULVR) is partnering with Accenture (NYSE: ACN) to scale the use of AI-enabled digital twins across its global manufacturing network

You can't refute it. Yes, I understand your level well.

Total nonsense! I have no interest in educating you.

She'll probably move to somewhere without any extradition treaty once the plug is finally pulled on this 'cancer vaccine' scam.?

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

WKSP Weekly chart: https://schrts.co/IIIuZpgy

I understand that Halozyme has not signed any exclusive agreements regarding treatments or indications related to Dupixent, so why is Sanofi collaborating with Alteogen?

Also, Halozyme's mdase patent is being invalidated due to Merck. Alteogen's technology is more advanced than Halozy

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

C V Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a

What reasonable expectation is there of PPS responding?
whether management can successfully execute on the vision they have laid out. Nobody cares about "the company" or "the management" or "their vision" or your two-bit-MBA-tutorials-in-a-post.

Enough of all that garbage.

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680761


IFUS STRONG

I get that, but that's not what I asked.

I'm not bullying you or accusing you of pumping.

You repeatedly point out what you consider to be nefarious shenanigans, so I asked: PPS hasn't effectively changed in THREE YEARS , other than a few short days 1 year ago this wee

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Linda lives in Missouri now but headquarters could be moved anywhere...or will they need it?

I think we're going to find out by the end of the sum

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters: